<DOC>
	<DOCNO>NCT02333955</DOCNO>
	<brief_summary>The primary objective study determine safety tolerability extend dose fix dose GCS-100 3 mg IV push patient Chronic Kidney Disease ( CKD ) .</brief_summary>
	<brief_title>A Phase 2 Extension Study GCS-100-CS-4003</brief_title>
	<detailed_description>Galectin-3 contributes fibrosis , elevate patient ESRD , correlate adverse outcome ( de Boer et . al. , 2011 , Dang et . al. , 2012 , Fernandes Bertocchi et . al. , 2008 , Henderson et . al. , 2008 ) . Animal model genetic knockout galectin-3 demonstrate reduction structural functional deficit kidney ( Dang et . al. , 2012 , Fernandes Bertocchi et . al. , 2008 , Henderson et . al. , 2008 ) . GCS-100 galectin-3 antagonist show reduce fibrosis pre-clinically . Based role galectin-3 fibrosis kidney disease , Sponsor believe GCS-100 may effective treat patient CKD . This study consist fix dose GCS-100 3mg IV push least every 30 day total 1 year follow-up 4 week last dose administer .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Subject capable understand purpose risk study able provide write informed consent 2 . Subject enrol GCS100CS4003 . 1 . Subject experience Grade 3 bad adverse event relate GCS100 clinical study GCS100CS4003 . 2 . Systolic blood pressure ≤90 mmHg ≥160 mmHg diastolic blood pressure ≤40 mmHg ≥100 mmHg screen 3 . Subject clinical laboratory value : Hemoglobin : ≤9 g/dL Total bilirubin : &gt; 1.5X upper limit normal ( ULN ) ALT and/or AST : &gt; 2.5X ULN 4 . Subject concomitant disease condition , include laboratory abnormality , , opinion investigator , could interfere conduct study put subject unacceptable risk . 5 . Subject may require renal replacement therapy within next 2 month , discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>